CENTOGENE NV (CNTG)
NL0014040206 - Common Stock
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is here and we're breaking down the biggest pre-market stock movers that traders need to know about this morning!
CENTOGENE Receives Nasdaq Non-Compliance Notice
CENTOGENE Receives Nasdaq Non-Compliance Notice
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated March 27, 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, indicating that the Company was not in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of the Nasdaq Listing Rules since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days (from February 12 through March 26, 2024). Nasdaq Rule 5450(a)(1) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days.
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and...
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected...
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities
CENTOGENE Explores Strategic Alternatives
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities...
CENTOGENE Explores Strategic Alternatives
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life...
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development...
CENTOGENE Receives French Research Tax Credit Accreditation
Partners able to claim up to 30% tax relief
CENTOGENE Receives French Research Tax Credit Accreditation
Partners able to claim up to 30% tax relief...
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
Collaboration to accelerate research to determine role of GBA gene
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
Collaboration to accelerate research to determine role of GBA gene...
CENTOGENE Announces Preliminary Full Year 2023 Revenue
CENTOGENE Announces Preliminary Full Year 2023 Revenue
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for...
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for...
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner...
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to...
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
Results From Landmark Study Published in Brain Journal
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
Results From Landmark Study Published in Brain Journal...
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering
Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering
Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology...
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner...
CENTOGENE Reports First Half 2023 Financial Results
Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance
CENTOGENE Reports First Half 2023 Financial Results
Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance...
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
Results from pivotal study published in Diagnostics journalConfirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher...
Centogene receives Nasdaq non-compliance notification (NASDAQ:CNTG)
Centogene (CNTG) on Thursday said it has received a written notification from Nasdaq indicating it is not in compliance with the continued listing rules.Nasdaq listing rule...
CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential...